QPRT Drives Breast Cancer Invasiveness via PLC-Linked Pathwa
2026-04-24
Liu et al. (2021) uncover how upregulation of quinolinate phosphoribosyltransferase (QPRT) promotes invasiveness in breast cancer through myosin light chain phosphorylation, implicating PLC signaling as a key mediator. Their integrative use of genetic and pharmacological inhibitors, including the PLC inhibitor U-73122, provides new mechanistic insight into cancer cell migration and highlights QPRT as a potential therapeutic target.
Jiedu Xiaozheng Yin Induces M1 Macrophage Polarization in CA
2026-04-23
This study demonstrates that Jiedu Xiaozheng Yin (JXY), a traditional Chinese medicine formula, inhibits the progression of colitis-associated colorectal cancer (CAC) by promoting macrophage polarization towards the pro-inflammatory M1 phenotype through TLR4 signaling. The findings highlight the therapeutic potential of immune modulation in CAC and provide mechanistic insight relevant for future translational research.
CP-673451 in Precision Oncology: Advanced PDGFR Inhibition I
2026-04-23
Explore how CP-673451, a selective PDGFRα/β inhibitor, is transforming cancer research through highly specific signaling pathway analysis and advanced tumor model applications. This article delivers a unique, evidence-driven perspective on optimizing experimental design with CP-673451.
Ziprasidone Hydrochloride (HCl): Mechanism and Research Evid
2026-04-22
Ziprasidone Hydrochloride (Ziprasidone HCl) is a second-generation antipsychotic with dual activity as a serotonin/dopamine receptor antagonist and a validated inhibitor of GOT1. It demonstrates antitumor efficacy in preclinical pancreatic cancer models and is supplied by APExBIO as SKU A5350 for research applications. This article details its mechanism, evidential benchmarks, and protocol integration for neuroscience and oncology research.
Bay 11-7821 (BAY 11-7082): Reliable IKK Inhibition for Cell
2026-04-22
This scenario-driven article helps biomedical researchers and lab technicians address common challenges in cell viability, apoptosis, and inflammatory pathway assays using Bay 11-7821 (BAY 11-7082), SKU A4210. Drawing on validated protocols, published data, and real-world use cases, we demonstrate how this selective IKK inhibitor delivers reproducible results for sensitive cancer and inflammation research workflows.
Senescence Gene Signature Predicts Prognosis in Cholangiocar
2026-04-21
This study establishes a machine learning-derived gene signature based on cellular senescence pathways to robustly predict prognosis and therapy response in cholangiocarcinoma. The findings advance the use of integrative bioinformatics for risk stratification and highlight potential functional biomarkers for clinical research.
Kif9 Motor Controls Centriolar Satellite Positioning in Inte
2026-04-21
Vicente et al. (2025) demonstrate that the kinesin motor Kif9 is essential for regulating the spatial distribution of centriolar satellites around the centrosome during interphase. Their work shows that loss of Kif9 leads to pericentrosomal satellite clustering, altered proteostasis, and subsequent defects in centrosome maturation and mitosis, highlighting the importance of Kif9-mediated satellite positioning for genomic stability.
AICAR Phosphate (Acadesine): Applied Workflows in B-CLL Rese
2026-04-20
Explore how AICAR phosphate (Acadesine) empowers apoptosis studies in B-cell chronic lymphocytic leukemia (B-CLL) and beyond, with optimized experimental protocols and troubleshooting strategies. This guide bridges mechanistic insight with actionable workflows, leveraging APExBIO’s high-purity reagent for reproducible and robust cancer research.
Tropifexor (LJN452): Precision FXR Modulation in Barrier & M
2026-04-20
Tropifexor (LJN452) offers ultra-potent, reproducible FXR pathway activation for metabolic and intestinal epithelial barrier research. This guide translates bench data into applied protocols and troubleshooting strategies, leveraging APExBIO’s trusted quality for high-impact experimental outcomes.
DMH1: Precision ALK2 Inhibition for Organoid and NSCLC Resea
2026-04-19
DMH1 empowers researchers to fine-tune BMP signaling, enabling robust control over stem cell fate and tumor proliferation in both organoid engineering and non-small cell lung cancer workflows. This guide delivers actionable protocols, troubleshooting insights, and contextualizes the latest evidence for maximizing DMH1's impact in advanced cellular models.
Sorafenib (BAY-43-9006): Applied Workflows in Cancer Biology
2026-04-18
Sorafenib (BAY-43-9006) is a powerful multikinase inhibitor used to dissect tumor signaling and antiangiogenic mechanisms across diverse cancer models. This guide delivers actionable protocols, troubleshooting strategies, and real-world applications, making it indispensable for translational cancer biology research.
Z-VAD-FMK: Translating Caspase Inhibition into Cancer Insigh
2026-04-17
This thought-leadership article unpacks the mechanistic and strategic value of Z-VAD-FMK (Benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone) for translational researchers targeting apoptosis and cell death pathways. We bridge new findings on non-apoptotic cancer cell death modalities from redox-active vitamin C studies with the practical deployment of APExBIO’s Z-VAD-FMK, offering advanced protocol guidance and a roadmap for leveraging caspase inhibition in high-impact cancer research.
METTL14-m6A-lncRNA Axis Modulates Colitis Inflammation
2026-04-16
This study reveals how METTL14-mediated m6A modification of the lncRNA DHRS4-AS1 regulates inflammation in ulcerative colitis by modulating the miR-206/A3AR axis. These findings expand our mechanistic understanding of epigenetic regulation in inflammatory bowel disease and suggest new experimental models for targeting RNA methylation pathways.
rTMS Promotes Cognitive Recovery in Alzheimer’s via Cx3cl1-C
2026-04-15
This study demonstrates that repetitive transcranial magnetic stimulation (rTMS) enhances cognitive recovery in Alzheimer’s disease by activating GABAergic neurons and upregulating the Cx3cl1-Cx3cr1 signaling axis, which in turn boosts microglial amyloid clearance. These findings highlight a non-invasive therapeutic strategy and clarify molecular mechanisms, supporting the translation of rTMS approaches in Alzheimer’s disease research.
Dual SMAD and Wnt Inhibition Drives Efficient iPSC to RGC Di
2026-04-14
This study demonstrates that simultaneous inhibition of SMAD and Wnt pathways enables highly efficient and reproducible differentiation of human induced pluripotent stem cells (iPSCs) into retinal ganglion cells (RGCs) without genetic modification. The protocol addresses previous variability and yield challenges, offering a robust platform to model optic neuropathies and potential regenerative therapies.
458 records 21/31 page Previous Next First page 上5页 2122232425 下5页 Last page